Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares KNSA
$96.12
+3.03%
at last close
Market Cap$7.33 billion
P/E Ratio—
Div Yield—
Volume861.3K
52-Week Range
$35.20$98.48
Analyst Ratings
- Consensus
- Buy — 7 Buy · 0 Hold · 0 Sell (7 analysts)
- Avg. Price Target
- $100.57 (+4.6% upside)
Key Stats
- Today's Range
- $91.74 – $96.28
- 50-Day Range
- $70.67 – $98.48
- 52-Week Range
- $35.20 – $98.48
- Volume
- 861K shs
- Average Volume
- 813K shs
- Market Cap
- $7.33 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.02%
- Days to Cover
- 1.00
About Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
Related Stocks
Compare head-to-head: KNSA vs LLY·KNSA vs JNJ·KNSA vs ABBV·KNSA vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.